Ticker Symbol: CUR
QUEBEC CITY, Dec. 6 /CNW Telbec/ - DiagnoCure announced today that the
Company will release its fourth quarter and fiscal 2007 year end results on
December 14, 2007, at approximately 5:00 p.m. (EST). This release will be
followed by a conference call, which will be held on Monday, December 17,
2007, at 10:00 a.m. (EST). The call will begin with a brief presentation,
followed by a question-and-answer period. A replay of the audio conference
will also be available on DiagnoCure's website at www.diagnocure.com as of
December 18, 2007, through a link on our Investors page.
To access the audio conference in realtime, please dial 1-800-733-7571.
We hope you'll be able to join us as we discuss our recent activities and
outlook for the future. We appreciate your continued support.
DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering lab services that increase
clinician and patient confidence in making critical treatment decisions.
DiagnoCure is currently preparing to launch the first GCC-based molecular test
for the management of colorectal cancer. In 2003, the Company entered into a
strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from GenProbe, and in Europe as the CEmarked PROGENSA(TM) PCA3
in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit
This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forwardlooking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein.
For further information:
For further information: Jean-Pierre Trudel, Jean-Pierre Trudel &
Associates, (514) 347-6111, email@example.com; DiagnoCure Inc., (418)